AstraZeneca's Subsidiary Launches Qtern Tablets for Type 2 Diabetes Treatment in India - (Fidelity via NewsPoints Desk)

  • AstraZeneca's has launched the type 2 diabetes drug Qtern in India, as reported in Fidelity.

  • In September, the company received the import and market permission from the Drugs Controller General of India for Qtern, a fixed-dose combination of dapagliflozin plus saxagliptin.

To read more NewsPoints articles, click here.